CAMBRIDGE, Mass.--(BUSINESS WIRE)--BioAxone
BioSciences, Inc. , an emerging, clinical-stage biotechnology
company focused on developing innovative drugs to treat spinal cord
injury and restore neurological function, today announced that CEO Lisa
McKerracher has accepted an offer to join the Consortium Advisory Panel
(CAP) for the Christopher
& Dana Reeve Foundation. In her new role, Dr. McKerracher will
direct the foundation’s focus toward the identification, development and
translation of potential Spinal Cord Injury (SCI) therapies into the
clinic. The Christopher Reeve Foundation wrote about Dr. McKerracher’s
accomplishments in a recent
blog post.

“This is a great honor,” said Lisa McKerracher, Ph.D., CEO of BioAxone
BioSciences. “The SCI community is really special to me and joining this
Advisory Board with the Reeve Foundation helps our shared goal of
advancing therapies for patients with SCI.”

Susan P. Howley, Executive Vice President Research, of the Christopher &
Dana Reeve Foundation commented, “We are thrilled that Lisa has joined
the Advisory Board of the Reeve Foundation. Her advancements and
dedication to the SCI field is something we greatly admire. We look
forward to continued progress toward our goals with her help.”

About the Reeve Foundation:

The Christopher & Dana Reeve Foundation is dedicated to curing spinal
cord injury by funding innovative research and improving the quality of
life for people living with paralysis through grants, information and
advocacy. The Paralysis Resource Center (PRC) is the support side of the
Reeve Foundation’s twin missions to provide “Today’s Care” and to strive
for “Tomorrow’s Cure” and offers a free, comprehensive, national source
of informational support for individuals living with paralysis and their
caregivers. For more information, visit www.christopherreeve.org

About BioAxone BioSciences

BioAxone BioSciences is an emerging, clinical-stage biotechnology
company developing innovative drugs to restore neurological function for
patients with Spinal Cord Injuries (SCI) and vascular malformations in
the central nervous system and glaucoma. Led by a team of scientists
renowned for their work on axon regeneration and neuronal signaling
pathways, BioAxone has a pioneering SCI drug currently in a Phase
IIb/III clinical trial with our partner, Vertex,
and is positioned to move other candidates into clinical trials.
BioAxone seeks global partners for a novel pipeline of first in class
compounds for neurological diseases with compromised blood-brain barrier
function and for glaucoma. For more information, visit www.bioaxonebio.com